STAT3 and B-cell non-Hodgkin lymphoma: At present, it is well known that interfering IL-6/JAK/STAT3 signaling pathway can slow down or inhibit the formation of melanoma, prostate cancer, and gastric tumors.38 The reason is that the blocking of this signaling pathway not only inhibits the content of downstream B-cell lymphoma/leukemia-X long molecules but also promotes the normal apoptosis of cells.